ArticleInternational journal of women's health2026
Efficacy of Misoprostol for Medical Treatment of Missed Miscarriage in Clinical Practice: A Single Saudi Center Experience.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate the success rate of misoprostol in managing missed miscarriages, identify factors affecting outcomes (such as gestational age and bleeding), and measure the rate of surgical intervention required after misoprostol use in Saudi Arabia due to the lack of data on this region. Patients and Methods: A retrospective cohort study was conducted at King Khalid University Hospital, Riyadh, Saudi Arabia, from 2019 to 2023. Women aged 18-45 years with a diagnosis of missed miscarriage and uterine size less than 12 weeks were included. Misoprostol was the primary treatment, while those who received primary surgical management were excluded. Data were collected from electronic medical records, including demographics, gestational age, misoprostol dosage, blood loss, and surgical indications. The primary outcome was successful medical management, defined as complete uterine evacuation without surgery. Complications such as heavy bleeding, hemoglobin drop, and transfusion were documented. Statistical analysis involved descriptive statistics and Fischer Results: A total 317 women met inclusion criteria. The success rate of misoprostol was 78.5%, with 58.3% achieving complete evacuation confirmed via ultrasound. Most patients had an empty uterus with a mean endometrial thickness of 11.1 mm. Retained products of conception (RPOC) were seen in 14.8% of cases. Complications were rare: 3.2% required transfusion and 21.5% needed surgical evacuation. Previous cesarean sections and misoprostol dose were significantly associated with higher complication rates and longer hospital stays (p < 0.05). Conclusion: Misoprostol is an effective, non-invasive treatment for missed miscarriage, with a high success rate and low complication risk. These findings support its use as a practical first-line treatment, potentially reducing the need for surgical intervention and associated healthcare burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.